Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cardiovasc Res
Главные авторы: Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Review Series from the Naples 2019 Joint Meeting of the ESC Working Groups on Myocardial Function and Cellular Biology of the Heart
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://ncbi.nlm.nih.gov/pubmed/31807773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvz278
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы